Sickle Cell Disease and Transfusion Dependent Beta-Thalassemia Treatment
We are looking to invite Haematologists to share their experience and opinions, so a newly developed interactive visual aid (IVA) can be optimised to support a potential new product launch in sickle cell disease and transfusion dependent beta-thalassemia. The client will choose some of the participants for the Phase 2 based on the feedback provided during the interviews – it will be up to you to decide if you want to proceed or not. If you are interested in taking part in this important study, please click below and apply.
Sickle Cell Disease and Transfusion Dependent Beta-Thalassemia Treatment
We are looking to invite Haematologists to share their experience and opinions, so a newly developed interactive visual aid (IVA) can be optimised to support a potential new product launch in sickle cell disease and transfusion dependent beta-thalassemia. The client will choose some of the participants for the Phase 2 based on the feedback provided during the interviews – it will be up to you to decide if you want to proceed or not. If you are interested in taking part in this important study, please click below and apply.
Sickle Cell Disease and Transfusion Dependent Beta-Thalassemia Treatment
We are looking to invite Haematologists to share their experience and opinions, so a newly developed interactive visual aid (IVA) can be optimised to support a potential new product launch in sickle cell disease and transfusion dependent beta-thalassemia. The client will choose some of the participants for the Phase 2 based on the feedback provided during the interviews – it will be up to you to decide if you want to proceed or not. If you are interested in taking part in this important study, please click below and apply.
Sickle Cell Disease and Transfusion Dependent Beta-Thalassemia Treatment
We are looking to invite Haematologists to share their experience and opinions, so a newly developed interactive visual aid (IVA) can be optimised to support a potential new product launch in sickle cell disease and transfusion dependent beta-thalassemia. The client will choose some of the participants for the Phase 2 based on the feedback provided during the interviews – it will be up to you to decide if you want to proceed or not. If you are interested in taking part in this important study, please click below and apply.